This present invention relates to BCMA binders (e.g. antibodies) and chimeric antigen receptor (CAR) constructs comprising a BCMA antigen binding molecule. The BCMA binders specifically bind to BCMA. The present BCMA CARs further comprise a hinge region (e.g., CD28 hinge), a transmembrane domain, and one or more intracellular NK cell signalling domains. NK cells expressing a BCMA CAR has increased efficacy in killing cancer cells. Provided herein also include therapeutic uses of the BCMA binders and BCMA CARs.

Provided are engineered cells containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy. In some embodiments, the engineered cells are hypoimmunogenic cells.

The present invention discloses a CD7-CAR-T cell, its preparation method and the application thereof, wherein the CD7-CAR-T cell comprises an antibody targeting the CD7 antigen or its antigen-binding fragment and the antibody or its antigen-binding fragment contains a heavy chain variable region of the antigen complementary determining region CDR1, CDR2 and CDR3 with the amino acid sequence as shown in SEQ ID NO.: 12-14; and a light chain variable region of the antigen complementary determining regions CDR1, CDR2 and CDR3 with the amino acid sequence as shown in SEQ ID NO.: 15-17. The antibody and the CD7-CAR based on the antibody fragment of the present invention have a strong affinity with CD7 antigen molecules.

This present invention relates to BCMA binders (e.g. antibodies) and chimeric antigen receptor (CAR) constructs comprising a BCMA antigen binding molecule. The BCMA binders specifically bind to BCMA. The present BCMA CARs further comprise a hinge region (e.g., CD28 hinge), a transmembrane domain, and one or more intracellular NK cell signalling domains. NK cells expressing a BCMA CAR has increased efficacy in killing cancer cells. Provided herein also include therapeutic uses of the BCMA binders and BCMA CARs.

Provided herein is a nucleic acid molecule comprising 5 to 3 a first nucleotide sequence encoding a safety switch polypeptide comprising a suicide moiety; a second nucleotide sequence encoding FOXP3; and a third nucleotide sequence encoding a chimeric antigen receptor (CAR); particularly wherein said first, second, and third nucleotide sequences are separated by nucleotide sequences encoding self-cleavage sequences. Also provided are constructs, vectors and cells comprising the nucleic acid molecule, and methods and uses for expressing the encoded polypeptides in cells, particularly in immune cells useful in adoptive cell therapy (ACT).

Provided are a disialoganglioside 2 (GD2) chimeric antigen receptor (CAR) and use thereof. A humanized GD2 single-chain variable fragment (scFv) antibody has activity of binding to a GD2 antigen, where the humanized GD2 scFv has a more than 80% of amino acid sequence identity with SEQ ID NO. 1. Further provided are the GD2 CAR and a chimeric antigen receptor T (CAR-T) cell expressing the GD2 CAR. The humanized GD2 scFv has better bioactivity and compatibility. Binding the GD2 CAR to GD2 has a better response effect, a stronger immune response and a better long-term effect. The CAR-T cell has higher safety and persistence and an extremely high application value.

The present invention provides a CAR-T cell targeting B7-H3 and an application thereof in the treatment of acute myeloid leukemia (AML). Specifically, the present invention provides a CAR-T cell targeting B7-H3, which comprises an scFv which targets B7-H3, a 41BB costimulatory signaling molecule and a CD3 domain. The B7-H3-CAR-T cell of the present invention has significant specific killing toward B7-H3 positive AML tumor cells. The results of animal experiments show that the B7-H3-CAR-T cell can significantly inhibit the growth of AML tumor cells in mice, significantly prolong the survival period of mice, and has a significant anti-tumor effect in vivo. The B7-H3-CAR-T cell of the present invention can be used as a novel therapeutic method for the targeted treatment of AML, and has huge clinical application prospects.

Compositions and methods for efficient cellular genomic engineering that transduce diverse cell types with minimal toxicity, leading to efficient and stable genomic modifications are described. The compositions and methods are applicable to development of chimeric antigen receptor engineered T cell therapy (CAR-T). An exemplary method introduces a gene of interest into cells by introducing to the cell a viral vector including a transposon encoding the gene of interest and mRNA including a sequence that encodes transposase enzymes configured to mediate targeted integration of the transposon into the cellular genome, whereby the mRNA is introduced to the cell via electroporation. Also disclosed are genetically modified cells and pharmaceutical compositions and methods of use thereof for treating subjects having diseases or disorders.

The present disclosure is directed to leucine zipper-based sorting systems adapted to facilitate the expression and coordination of polypeptide sequences capable of improving the function of CAR T cells. The systems enable the generation of T cells engineered to express multiple combinations of CARs (multi-CAR), safety-switches, switch receptors, and/or cytokines.

This present invention relates to BCMA binders (e.g. antibodies) and chimeric antigen receptor (CAR) constructs comprising a BCMA antigen binding molecule. The BCMA binders specifically bind to BCMA. The present BCMA CARs further comprise a hinge region (e.g., CD28 hinge), a transmembrane domain, and one or more intracellular NK cell signalling domains. NK cells expressing a BCMA CAR has increased efficacy in killing cancer cells. Provided herein also include therapeutic uses of the BCMA binders and BCMA CARs.